ANX-005

DB16977InvestigationalProtein Based Therapies

ANX-005: Overview.

Mechanism: Pharmacologically active on Complement component 1q (C1q)
Curator reviewed
Also known as: Humanized Igg4 Monoclonal Antibody Binding To Human C1Q
Code names: ANX-005

Resolves to

Compound

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which companies are running trials of ANX-005, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.